We investigated whether S100A4 level is associated with pathophysiology of unstable angina pectoris (UAP), and its potential prognostic value for subsequent cardiovascular events. We compared plasma levels of S100A4 and a set of clinical markers in three groups (59 with UAP, 32 with stable angina pectoris and 30 healthy controls). S100A4 levels in patients with UAP were significantly elevated. In UAP group, baseline S100A4 levels were significantly higher in patients with subsequent cardiovascular events than those without, a positive correlation was identified between the risk of subsequent cardiovascular events and the plasma levels of S100A4. Elevated S100A4 levels may be involved in the pathogenesis of UAP, and may be a marker predictive of post-treatment cardiovascular events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/bmm-2019-0137 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease.
J Inflamm Res
January 2025
Department of Infectious Disease, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People's Republic of China.
Chronic liver disease ranks as the 11th leading cause of death worldwide, while hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality, representing a substantial risk to public health. Over the past few decades, the global landscape of chronic liver diseases, including hepatitis, metabolic dysfunction-associated steatotic liver disease (MASLD), liver fibrosis, and HCC, has undergone substantial changes. Copper, a vital trace element for human health, is predominantly regulated by the liver.
View Article and Find Full Text PDFPrognostic value of TIMI risk score combined with systemic immune-inflammation index and lipoprotein(a) in patients with ST-Segment elevation myocardial infarction after percutaneous coronary intervention.
Int J Cardiol Heart Vasc
February 2025
Department of Cardiology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225000, China.
Background: Thrombolysis in Myocardial Infarction (TIMI) risk score in patients with ST-segment elevation myocardial infarction (STEMI) is associated with major adverse cardiovascular events (MACE). This study aimed to develop a prediction model based on the TIMI risk score for MACE in STEMI patients after percutaneous coronary intervention (PCI).
Methods: We conducted a retrospective data analysis on 290 acute STEMI patients admitted to the Affiliated Hospital of Yangzhou University from January 2022 to June 2023 and met the inclusion criteria.
Effect of hybrid blood purification on nutritional status, inflammation, and cardiovascular events in patients with end-stage renal disease.
Pak J Med Sci
January 2025
Rong Zou Department of Nephrology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan Province 421002, P.R. China.
Objective: To explore the effects of hybrid blood purification on nutritional status and cardiovascular events in patients with end-stage renal disease (ESRD).
Methods: A total of 135 patients with ESRD who received treatment in The Affiliated Nanhua Hospital of Hengyang Medical School from March 2021 to June 2023 were included in this retrospective study. Of them, 66 patients were treated with hemodialysis purification (hemodialysis group), and 69 patients underwent hybrid blood purification (hybrid group).
Inflammatory bowel disease is associated with an increased risk of cardiovascular events in a sex and age-dependent manner: A historical cohort study.
Int J Cardiol Cardiovasc Risk Prev
March 2025
Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, 6997801, Israel.
Background: The relationship between inflammatory bowel diseases (IBD) and the risk of ischemic heart diseases (IHD) remains a subject of debate. In this study, we sought to investigate the association between IBD and long-term risk of IHD in a substantial cohort of IBD patients.
Methods: In this retrospective cohort study we utilized data from a state-mandated provider in Israel (Maccabi Healthcare Services).
Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
Am J Prev Cardiol
March 2025
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, University of California Los Angeles, Los Angeles, CA, USA.
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown benefits in improving cardiovascular (CV) outcomes in patients with heart failure (HF) and may mitigate symptom progression in myocardial infarction (MI). However, their effectiveness in patients with type 2 diabetes and MI undergoing percutaneous coronary intervention (PCI) is unclear.
Methods: To identify eligible studies, a comprehensive search of electronic databases, PubMed, Cochrane Library, Scopus and Embase, was conducted from inception until May 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!